Nausea and vomiting are among the most prevalent and disturbing side effects of chemotherapy.1,2 These side effects may lead to several adverse impacts in patients receiving chemotherapeutic agents, such as decreased quality of life, anxiety, depression, and lack of compliance to the medication.2,3 Chemotherapy-induced nausea and vomiting (CINV) is classified into 3 types: acute CINV, which occurs during the first 24 hours postchemotherapy; delayed CINV, which begins after24 hours postchemotherapy and may last for up to 6 or 7 days; and finally anticipatory CINV, which affects people who have experienced severe nausea and vomiting in their previous administrations of chemotherapeutic agents. AbstractBackground. Nausea and vomiting are among the most prevalent and disturbing side effects of chemotherapy. Therefore, there is a need for additional antiemetic agents that could effectively reduce chemotherapy-induced nausea and vomiting (CINV), whether alone or in combination with current standard therapies. Since clinical data on the effectiveness of ginger in patients with advanced breast cancer is lacking, the present study aimed to evaluate the effects of ginger against both acute and delayed forms of CINV in a population with advanced breast cancer as the main malignancy. Methods. In this pilot, randomized, open-label clinical trial, 100 women (mean age = 51.83 ± 9.18 years) with advanced breast cancer who were initially assigned to standard chemotherapy protocol with docetaxel, epirubicin, and cyclophosphamide (the TEC regimen) were randomized to receive ginger (1.5 g/d in 3 divided doses every 8 hours) plus standard antiemetic regimen (granisetron plus dexamethasone; the ginger group) or standard antiemetic regimen alone (control group). The duration of treatment with ginger was specified to 4 days from the initiation of chemotherapy. Prevalence, score, and severity of nausea, vomiting, and retching were assessed using a simplified form of Rhodes index in the first 6 hours, between 6 to 24 hours, and days 2, 3, and 4 postchemotherapy. Results. A significantly lower prevalence of nausea was observed in the ginger group during 6 to 24 hours postchemotherapy. Despite this effect, no other significant additional benefit from ginger (1.5 g/d) was observed against prevalence or severity of nausea, vomiting, and retching in any of the assessed periods. Conclusion. Addition of ginger (1.5 g/d) to standard antiemetic therapy (granisetron plus dexamethasone) in patients with advanced breast cancer effectively reduces the prevalence of nausea 6 to 24 hours postchemotherapy. However, there is no other additional advantage for ginger in reducing prevalence or severity of acute or delayed CINV.
Background. Prolactin (PRL) level is proposed to be associated with the severity of psoriasis although the previous studies reported different results. Objective. To find the association between PRL levels and severity of psoriasis before and after treatment. In addition, we aimed to find a difference in prolactin, thyroid stimulating hormone (TSH), thyroid hormones (T3 and T4), and cortisol levels between patients with psoriasis and normal controls. Methods. First, the levels of hormones were measured in 30 patients with psoriasis and 30 matched controls. The severity was assessed by psoriasis area and severity index (PASI). Then, patients were treated, and PASI was assessed every week until achieving PASI-75 response. At this time, the hormones were measured again and compared to the baseline. Results. No statistical significant difference was observed in the mean PRL, T3, T4, TSH, and cortisol levels between cases and controls. Comparing to the baseline, a significant decrease in PRL levels and a significant increase in T3 and serum cortisol levels were observed after treatment (P < 0.05), while the changes in other hormones were not significant. Conclusion. After treatment, PRL significantly decreased, and T3 and cortisol levels significantly increased. No correlation between hormone levels and improvement of PASI score existed.
Aim: Chlorella vulgaris is a unicellular green microalga with several pharmacological activities including anti‐hyperlipidemic effects. In spite of interesting preclinical findings, the clinical efficacy of C. vulgaris in dyslipidemia—whether alone or in combination with statins—has not been clarified. The present study aimed to investigate the impact of supplementation with C. vulgaris as an adjunctive therapy to atorvastatin in dyslipidemic subjects. Methods: In a randomised, open‐label clinical trial, 100 dyslipidemic subjects were randomly assigned to: (i) Chlorella group (n = 50, dropouts = 24), receiving C. vulgaris (600 mg/day) + atorvastatin (20 mg/day) for 8 weeks; or (ii) atorvastatin group (n = 50, dropouts = 13), receiving only atorvastatin (20 mg/day) for 8 weeks. Lipid profile and biomarkers of muscular, hepatic and renal injury were determined at baseline and at the end of the trial. Results: There were significant reductions in serum total cholesterol (P < 0.001), low‐density lipoprotein cholesterol (P < 0.001) and triglycerides (P= 0.006 in Chlorella and P= 0.004 in atorvastatin group) in both groups. No significant change in serum high‐density lipoprotein cholesterol levels was observed in any of the groups. Serum aspartate aminotransferase levels were raised in both Chlorella (P= 0.034) and atorvastatin (P= 0.002) groups, whereas alkaline phosphatase was only elevated in the Chlorella group (P= 0.028). In comparison with baseline values, no significant change was observed in serum levels of alanine aminotransferase, creatine phosphokinase, creatinine, blood urea nitrogen and fasting blood sugar. Conclusion: Based on the results, addition of C. vulgaris to atorvastatin therapy for 8 weeks does not appear to be associated with an improved control of serum lipid profile.
It seems that Nigella might have the same efficacy as Betamethasone in improvement of life quality and decreasing severity of hand eczema.
Fibroblasts had excellent adherence to and viability on the acellular amniotic membrane, which seems to provide an acceptable temporary skin substitute that can be used for wounds.
Fibroblast injection has been shown to promote healing of RDEB wounds and is superior to FAMS or the control treatment.
Introduction: Ablative and nonablative lasers have been used to treat melasma. We aimed to assess and compare the combining Q-switched Nd:YAG laser (QSNYL) and fractional erbium:YAG laser (FEYL) with QSNYL alone in treatment of melasma. Methods: This randomized controlled clinical trial was performed in our Research Center during 2013-2014. Women with melasma and without a history of keloid formation, hypersensitivity to hydroquinone, or pigmentary changes due to laser therapy were randomly allocated to receive four sessions of either QSNYL-FEYL combination or QSNYL alone. All patients received topical treatment with Kligman's formula. Before laser therapy and 4 weeks after the last treatment session, patients' skin was assessed for changes in skin color, melanin content, and erythema intensity of melasma lesions quantitatively. ; P < 0.001). After adjustment for baseline values, the post treatment intensity of erythema was significantly lower in QSNYL-FEYL group (P < 0.001). The patients reported no adverse events. Conclusion: QSNYL-FEYL was significantly more effective in decreasing melanin content of lesions than QSNYL and led to a lighter skin.
The present study evaluated the potential benefit of supplementation with Heracleum persicum as an adjunctive therapy to atorvastatin in dyslipidemic subjects. In a randomized, open-label, clinical trial, 100 dyslipidemic subjects were randomly assigned to: (1) H. persicum group (n = 50, completers = 18), receiving H. persicum extract (500 mg/day) + atorvastatin (10 mg/day) for 8 weeks, or (2) atorvastatin group (n =50, completers= 34), receiving only atorvastatin (20 mg/day) for 8 weeks. Weight, body mass index (BMI), lipid profile, and biomarkers of hepatic and renal injury were determined at baseline and at the end of the trial. There were significant reductions in serum total cholesterol and LDL-C in both the H. persicum (p = 0.001) and atorvastatin (p < 0.05) groups. Serum HDL-C was elevated in the atorvastatin group (p < 0.05), while no significant change was observed in the H. persicum group (p > 0.05). Serum triglyceride levels remained statistically unchanged by the end of the trial in both groups (p > 0.05). Serum alanine (p = 0.049) and aspartate aminotransferase (p = 0.013) levels rose in the atorvastatin, but not the H. persicum (p > 0.05) group. In comparison with baseline values, no significant change was observed in weight and BMI, as well as serum levels of creatinine, blood urea nitrogen, and fasting blood sugar in either of the groups (p > 0.05). Apart from HDL-C, the effects of atorvastatin (20 mg/day) on other lipid profile parameters do not appear to be significantly superior to those achieved by combination therapy with H. persicum + atorvastatin (10 mg/day).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
334 Leonard St
Brooklyn, NY 11211
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.